Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2024-04-10 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司对会计师事务所2023年度履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report by 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) on the performance of 北京兴华会计师事务所 (Beijing Xinghua CPA Firm) for the 2023 audit year. It references auditing standards, the audit of the 2023 financial report and internal controls, and the issuance of an unqualified audit opinion. The document is a standalone audit evaluation report focusing on the auditor's performance and audit process, not the full annual report itself. It does not contain the full financial statements or comprehensive company activity details typical of an Annual Report (10-K). The document length is short (1262 characters), and it is a detailed audit performance evaluation rather than a mere announcement. Therefore, it fits best under Audit Report / Information (AR). FY 2023
2024-04-10 Chinese
哈药集团股份有限公司2023年度内部控制审计报告
Regulatory Filings
2024-04-10 Chinese
哈药集团股份有限公司2023年度独立董事述职报告—潘广成
Board/Management Information Classification · 95% confidence The document is titled '2023 年度独立董事述职报告' which translates to '2023 Annual Independent Director's Work Report'. It details the independent director's personal background, independence statement, annual duties, attendance at board and shareholder meetings, communication with audit firms, oversight of financial reports, and evaluation of company governance and internal controls. The document does not contain financial statements or detailed financial data but is a narrative report on the independent director's activities and assessments during the year. It is not an annual report, audit report, or financial statement. It is a management-related report focusing on board and governance activities, specifically the independent director's duties and evaluations. Therefore, the document fits best under Board/Management Information (MANG) as it relates to the independent director's role and board activities rather than financial results or regulatory filings.
2024-04-10 Chinese
哈药集团股份有限公司2023年度独立董事述职报告—李兆华
Board/Management Information Classification · 95% confidence The document is titled '2023 年度独立董事述职报告' which translates to '2023 Annual Independent Director's Work Report'. It details the independent director's background, duties performed during the year, participation in board and committee meetings, supervision activities, communication with auditors, and evaluation of company governance and financial reporting. The document includes detailed descriptions of the director's oversight of financial reports, internal controls, audit committee activities, and corporate governance matters. It is a comprehensive report on the independent director's annual duties and performance rather than a general annual report or financial statement. This type of document fits the category of Board/Management Information (MANG), as it relates to the activities and reports of board members, specifically independent directors. The document length (5656 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is MANG with high confidence.
2024-04-10 Chinese
会计师事务所对公司控股股东及其关联方占用资金情况的专项说明
Regulatory Filings
2024-04-10 Chinese
哈药集团股份有限公司2023年年度报告_摘要
Annual Report Classification · 95% confidence The document is titled as "2023 年年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed financial data for the year 2023, including revenue, net profit, quarterly breakdowns, shareholder information, business overview, industry context, and accounting data. The length is 9607 characters, which is substantial and contains actual financial statements and analysis. The document is not a brief announcement or a certification but a comprehensive summary of the annual report. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-04-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.